AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical ... has announced the completion of its acquisition of Nimble Therapeutics, a move aimed at strengthening its research and development pipeline ...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...

Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

Under the leadership of Rob Michael, AbbVie continues to make tremendous progress in developing its immunology and ...

AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion of its acquisition of ...